Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dokmak, Amr, Almeqdadi, Mohammad, Trivedi, Hirsh, Krishnan, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669193/
https://www.ncbi.nlm.nih.gov/pubmed/31388398
http://dx.doi.org/10.4254/wjh.v11.i7.562
_version_ 1783440329167339520
author Dokmak, Amr
Almeqdadi, Mohammad
Trivedi, Hirsh
Krishnan, Sandeep
author_facet Dokmak, Amr
Almeqdadi, Mohammad
Trivedi, Hirsh
Krishnan, Sandeep
author_sort Dokmak, Amr
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medications has been studied with mixed results. In this review, we discuss the use of anti-diabetic medications in the management of NAFLD with a specific focus on sodium-glucose cotransporter 2 inhibitors. We shed light on the evidence supporting their use in detail and discuss limitations and future directions.
format Online
Article
Text
id pubmed-6669193
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-66691932019-08-06 Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease Dokmak, Amr Almeqdadi, Mohammad Trivedi, Hirsh Krishnan, Sandeep World J Hepatol Review Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medications has been studied with mixed results. In this review, we discuss the use of anti-diabetic medications in the management of NAFLD with a specific focus on sodium-glucose cotransporter 2 inhibitors. We shed light on the evidence supporting their use in detail and discuss limitations and future directions. Baishideng Publishing Group Inc 2019-07-27 2019-07-27 /pmc/articles/PMC6669193/ /pubmed/31388398 http://dx.doi.org/10.4254/wjh.v11.i7.562 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Dokmak, Amr
Almeqdadi, Mohammad
Trivedi, Hirsh
Krishnan, Sandeep
Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
title Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
title_full Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
title_fullStr Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
title_full_unstemmed Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
title_short Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
title_sort rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669193/
https://www.ncbi.nlm.nih.gov/pubmed/31388398
http://dx.doi.org/10.4254/wjh.v11.i7.562
work_keys_str_mv AT dokmakamr riseofsodiumglucosecotransporter2inhibitorsinthemanagementofnonalcoholicfattyliverdisease
AT almeqdadimohammad riseofsodiumglucosecotransporter2inhibitorsinthemanagementofnonalcoholicfattyliverdisease
AT trivedihirsh riseofsodiumglucosecotransporter2inhibitorsinthemanagementofnonalcoholicfattyliverdisease
AT krishnansandeep riseofsodiumglucosecotransporter2inhibitorsinthemanagementofnonalcoholicfattyliverdisease

Ejemplares similares